VectivBio (VECT) Stock Price, News & Analysis

Company Overview

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.

Key Stats

• Today's Range: $16.85 to $16.85
• 50-Day Range: $16.85 to $16.85
• 52-Week Range: $4.25 to $16.98
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $573.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

VECT Stock Analysis - Frequently Asked Questions

How have VECT shares performed this year?

VectivBio's stock was trading at $16.85 at the beginning of 2025. Since then, VECT stock has increased by 0.0% and is now trading at $16.85.
View the best growth stocks for 2025 here.

When did VectivBio IPO?

VectivBio (VECT) raised $128 million in an initial public offering on Friday, April 9th 2021. The company issued 7,500,000 shares at $16.00-$18.00 per share. BofA Securities, SVB Leerink and Credit Suisse served as the underwriters for the IPO and LifeSci Capital was co-manager.

How do I buy shares of VectivBio?

Shares of VECT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of VectivBio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that VectivBio investors own include Axcelis Technologies (ACLS), NVIDIA (NVDA), ASML (ASML), Super Micro Computer (SMCI), Bel Fuse (BELFB), inTEST (INTT) and Rockwell Medical (RMTI).

Company Calendar

• Today: 5/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VECT
• CIK: 1836379
• Web: vectivbio.com
• Phone: 41-61-551-3030
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $27.34 million
• Price / Sales: 20.97
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 34,020,000
• Free Float: N/A
• Market Cap: $573.24 million
• Optionable: No Data
• Beta: 0.11